Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 407 results
Filters: Keyword is Male  [Clear All Filters]
Found 407 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

M

Mulligan K, Parker RA, Komarow L, et al. "Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial." J. Acquir. Immune Defic. Syndr.. 2006;41(5):590-7.
Gross R, Tierney C, Andrade A, et al. "Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial." Arch. Intern. Med.. 2009;169(13):1224-32.
Schifitto G, Zhang J, Evans SR, et al. "A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment." Neurology. 2007;69(13):1314-21.
J Critchfield W, Lemongello D, Walker DH, et al. "Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection." J. Virol.. 2007;81(11):5460-71.
Robertson K, Kumwenda J, Supparatpinyo K, et al. "A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings." J. Neurovirol.. 2011;17(5):438-47.
Verma A, Bradford Y, Verma SS, et al. "Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2017;27(3):101-111.
Stone ND, Dunaway SB, Flexner C, et al. "Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects." Antimicrob. Agents Chemother.. 2007;51(7):2351-8.

O

Van Epps P, Matining RM, Tassiopoulos K, et al. "Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy." PLoS ONE. 2014;9(9):e107064.
Kalayjian RC, Spritzler J, Matining RM, et al. "Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction." AIDS. 2013;27(10):1563-71.
Hulgan T, Donahue JP, Smeaton L, et al. "Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors." Eur. J. Clin. Pharmacol.. 2009;65(11):1081-8.
Kearney MF, Wiegand A, Shao W, et al. "Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy." J. Virol.. 2016;90(3):1369-76.
Périssé ARS, Smeaton L, Chen Y, et al. "Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease." PLoS ONE. 2013;8(12):e83643.
Smith KY, Tierney C, Mollan K, et al. "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine." Clin. Infect. Dis.. 2014;58(4):555-63.
Hulgan T, Hughes M, Sun X, et al. "Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study." J. Acquir. Immune Defic. Syndr.. 2006;42(4):450-4.
Kelesidis T, Jackson N, McComsey GA, et al. "Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection." AIDS. 2016;30(17):2625-2633.

P

Genberg BL, Wilson IB, Bangsberg DR, et al. "Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America." AIDS. 2012;26(11):1415-23.
Lee AJ, Bosch RJ, Evans SR, et al. "Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen." J. Neurovirol.. 2015;21(2):210-8.
McComsey GA, Kitch D, Sax PE, et al. "Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s." Clin. Infect. Dis.. 2011;53(2):185-96.
Tebas P, Zhang J, Hafner R, et al. "Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110." J. Antimicrob. Chemother.. 2009;63(5):998-1005.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Evans SR, Ellis RJ, Chen H, et al. "Peripheral neuropathy in HIV: prevalence and risk factors." AIDS. 2011;25(7):919-28.
Shivakoti R, Yang W-T, Berendes S, et al. "Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings." J. Infect. Dis.. 2016;213(7):1074-8.
Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.
Haas DW, Bartlett JA, Andersen JW, et al. "Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration." Clin. Infect. Dis.. 2006;43(6):783-6.

Pages